Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer.
AJR Am J Roentgenol
; 208(2): 290-299, 2017 Feb.
Article
en En
| MEDLINE
| ID: mdl-27809573
OBJECTIVE: Neoadjuvant chemotherapy is becoming the standard of care for patients with locally advanced breast cancer. Conventional imaging modalities used for the assessment of tumor response to neoadjuvant chemotherapy rely on changes in size or morphologic characteristics and, therefore, are inherently limited. CONCLUSION: Functional imaging technologies evaluate vascular, metabolic, biochemical, and molecular changes in cancer cells and have a unique ability to detect specific biologic tumor markers, assess therapeutic targets, predict early response to neoadjuvant chemotherapy, and guide individualized cancer therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Mamografía
/
Monitoreo de Drogas
/
Terapia Neoadyuvante
/
Imagen Multimodal
Tipo de estudio:
Prognostic_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
AJR Am J Roentgenol
Año:
2017
Tipo del documento:
Article
Pais de publicación:
Estados Unidos